Total Payments
$53,685
2024 Payments
$66.77
Companies
8
Transactions
37
Medicare Patients
909
Medicare Billing
$274,983
Payment Breakdown by Category
Other$31,940 (59.5%)
Research$14,064 (26.2%)
Consulting$3,791 (7.1%)
Travel$2,824 (5.3%)
Food & Beverage$1,067 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $31,940 | 10 | 59.5% |
| Unspecified | $14,064 | 1 | 26.2% |
| Consulting Fee | $3,791 | 3 | 7.1% |
| Travel and Lodging | $2,824 | 8 | 5.3% |
| Food and Beverage | $1,067 | 15 | 2.0% |
Payments by Type
General
$39,621
36 transactions
Research
$14,064
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Therapeutics plc | $19,582 | 17 | $0 (2023) |
| Horizon Pharma plc | $16,018 | 14 | $0 (2018) |
| Ardelyx, Inc. | $14,064 | 1 | $0 (2022) |
| Keryx Biopharmaceuticals, Inc. | $3,700 | 1 | $0 (2017) |
| Retrophin, Inc. | $101.66 | 1 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $79.89 | 1 | $0 (2023) |
| BARD PERIPHERAL VASCULAR, INC. | $72.61 | 1 | $0 (2019) |
| Amgen Inc. | $66.77 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $66.77 | 1 | Amgen Inc. ($66.77) |
| 2023 | $108.26 | 2 | Novartis Pharmaceuticals Corporation ($79.89) |
| 2022 | $15,855 | 3 | Ardelyx, Inc. ($14,064) |
| 2021 | $7,791 | 5 | Horizon Therapeutics plc ($7,791) |
| 2020 | $1,320 | 1 | Horizon Therapeutics plc ($1,320) |
| 2019 | $8,725 | 9 | Horizon Therapeutics plc ($8,652) |
| 2018 | $7,804 | 6 | Horizon Pharma plc ($7,702) |
| 2017 | $12,016 | 10 | Horizon Pharma plc ($8,316) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/24/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $66.77 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/05/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $79.89 | General |
| 11/03/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $28.37 | General |
| Category: KRYSTEXXA | ||||||
| 11/17/2022 | Horizon Therapeutics plc | PROCYSBI (Drug) | Honoraria | Cash or cash equivalent | $1,760.00 | General |
| Category: PROCYSBI | ||||||
| 11/05/2022 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $31.05 | General |
| Category: KRYSTEXXA | ||||||
| 01/18/2022 | Ardelyx, Inc. | — | — | Cash or cash equivalent | $14,064.00 | Research |
| Study: A Randomized, Open-Label Study to Evaluate the Use of Tenapanor as the Core Therapy in the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis who are Phosphate Binder Naive or on Phosphate Binder Therapy, to Optimize Phosphorus | ||||||
| 10/15/2021 | Horizon Therapeutics plc | PROCYSBI (Drug) | Honoraria | Cash or cash equivalent | $3,740.00 | General |
| Category: PROCYSBI | ||||||
| 09/23/2021 | Horizon Therapeutics plc | TEPEZZA (Drug) | Honoraria | Cash or cash equivalent | $1,980.00 | General |
| Category: TEPEZZA | ||||||
| 09/23/2021 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Consulting Fee | In-kind items and services | $42.00 | General |
| Category: KRYSTEXXA | ||||||
| 04/22/2021 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Honoraria | Cash or cash equivalent | $1,980.00 | General |
| Category: KRYSTEXXA | ||||||
| 04/22/2021 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Consulting Fee | In-kind items and services | $48.50 | General |
| Category: KRYSTEXXA | ||||||
| 12/11/2020 | Horizon Therapeutics plc | PROCYSBI (Drug) | Honoraria | Cash or cash equivalent | $1,320.00 | General |
| Category: PROCYSBI | ||||||
| 12/13/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Travel and Lodging | Cash or cash equivalent | $1,323.84 | General |
| Category: KRYSTEXXA | ||||||
| 12/13/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Travel and Lodging | Cash or cash equivalent | $231.31 | General |
| Category: KRYSTEXXA | ||||||
| 12/13/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $141.83 | General |
| Category: KRYSTEXXA | ||||||
| 12/13/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $69.00 | General |
| Category: KRYSTEXXA | ||||||
| 12/13/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: KRYSTEXXA | ||||||
| 12/13/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $35.20 | General |
| Category: KRYSTEXXA | ||||||
| 12/01/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Honoraria | Cash or cash equivalent | $6,640.00 | General |
| Category: KRYSTEXXA | ||||||
| 12/01/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Travel and Lodging | Cash or cash equivalent | $146.00 | General |
| Category: KRYSTEXXA | ||||||
| 02/22/2019 | BARD PERIPHERAL VASCULAR, INC. | — | Food and Beverage | In-kind items and services | $72.61 | General |
| 12/12/2018 | Horizon Pharma plc | KRYSTEXXA (Drug) | Honoraria | Cash or cash equivalent | $660.00 | General |
| Category: KRYSTEXXA | ||||||
| 10/12/2018 | Horizon Pharma plc | KRYSTEXXA (Drug) | Honoraria | Cash or cash equivalent | $660.00 | General |
| Category: KRYSTEXXA | ||||||
| 08/16/2018 | Horizon Pharma plc | KRYSTEXXA (Drug) | Food and Beverage | Cash or cash equivalent | $86.93 | General |
| Category: KRYSTEXXA | ||||||
| 07/20/2018 | Horizon Pharma plc | KRYSTEXXA (Drug) | Honoraria | Cash or cash equivalent | $6,160.00 | General |
| Category: KRYSTEXXA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Open-Label Study to Evaluate the Use of Tenapanor as the Core Therapy in the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis who are Phosphate Binder Naive or on Phosphate Binder Therapy, to Optimize Phosphorus | Ardelyx, Inc. | $14,064 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 183 | 421 | $221,886 | $60,247 |
| 2022 | 5 | 155 | 344 | $175,703 | $49,192 |
| 2021 | 8 | 255 | 523 | $252,693 | $70,556 |
| 2020 | 9 | 316 | 788 | $365,343 | $94,989 |
Total Patients
909
Total Services
2,076
Medicare Billing
$274,983
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 39 | 168 | $167,328 | $44,584 | 26.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 47 | 100 | $19,700 | $6,012 | 30.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 44 | 83 | $17,845 | $5,438 | 30.5% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 27 | 41 | $10,578 | $2,228 | 21.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 15 | 17 | $5,151 | $1,533 | 29.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 11 | 12 | $1,284 | $451.80 | 35.2% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 32 | 130 | $129,480 | $35,826 | 27.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 52 | 102 | $20,094 | $5,518 | 27.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 44 | 79 | $16,985 | $5,432 | 32.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 11 | 14 | $4,242 | $1,350 | 31.8% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 16 | 19 | $4,902 | $1,066 | 21.7% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 35 | 168 | $167,328 | $46,872 | 28.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 74 | 142 | $27,974 | $7,258 | 25.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 49 | 92 | $19,780 | $6,753 | 34.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 27 | 27 | $14,850 | $4,201 | 28.3% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 31 | 51 | $13,158 | $2,596 | 19.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 15 | 17 | $5,151 | $1,722 | 33.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 12 | 14 | $2,772 | $782.88 | 28.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 12 | 12 | $1,680 | $369.74 | 22.0% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2020 | 46 | 291 | $260,277 | $65,227 | 25.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 86 | 192 | $34,118 | $10,848 | 31.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 58 | 129 | $25,785 | $7,005 | 27.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 27 | 27 | $13,970 | $4,155 | 29.7% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2020 | 35 | 61 | $14,178 | $3,554 | 25.1% |
| 90945 | Dialysis procedure including one evaluation | Facility | 2020 | 11 | 27 | $7,649 | $1,835 | 24.0% |
About Dr. Anthony Bleyer, MD
Dr. Anthony Bleyer, MD is a Nephrology healthcare provider based in Winston Salem, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1346225778.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Bleyer, MD has received a total of $53,685 in payments from pharmaceutical and medical device companies, with $66.77 received in 2024. These payments were reported across 37 transactions from 8 companies. The most common payment nature is "Honoraria" ($31,940).
As a Medicare-enrolled provider, Bleyer has provided services to 909 Medicare beneficiaries, totaling 2,076 services with total Medicare billing of $274,983. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Winston Salem, NC
- Active Since 12/08/2005
- Last Updated 01/07/2008
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1346225778
Products in Payments
- KRYSTEXXA (Drug) $16,018
- KRYSTEXXA (Biological) $10,849
- PROCYSBI (Drug) $6,820
- Auryxia (Drug) $3,700
- TEPEZZA (Drug) $1,980
- (815) Thiola (Drug) $101.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Winston Salem
Michael Rocco, Md, MD
Nephrology — Payments: $69,160
Nephrology $69,160
Barry Freedman, Md, MD
Nephrology — Payments: $65,584
Nephrology $65,584
Nicholas Mclean, Md, MD
Nephrology — Payments: $13,646
Nephrology $13,646
Scott Satko, Md, MD
Nephrology — Payments: $9,542
Nephrology $9,542
Dr. Taewoo Lee, Md, Phd, MD, PHD
Nephrology — Payments: $8,546
Nephrology $8,546
Andrew Spangler, Md, MD
Nephrology — Payments: $7,307
Nephrology $7,307